公开(公告)号：WO2013075823A1

公开(公告)日：2013-05-30

申请号：PCT/EP2012/004818

申请日：2012-11-21

Applicant: ALFRED E. TIEFENBACHER (GMBH & CO. KG) ,  AMW GMBH

Inventor： SAHR, Florian ,  LANG, Susanne ,  RYBACH, Simon ,  FITZNER, Ansgar

IPC: A61K31/381 ,  A61K9/70 ,  A61P25/16 ,  A61P25/14 ,  A61P25/28

CPC classification number: A61K31/381 ,  A61K9/7053

Abstract: The present invention relates to an inventive transdermal therapeutic system (TTS) comprising rotigotine, a pharmaceutically acceptable adhesive comprising styrene butadiene block copolymer and a crystallization inhibitor, an inventive matrix with an extended release of rotigotine suitable for a transdermal therapeutic system, an inventive production method of a respective matrix or a respective TTS comprising rotigotine, as well as uses of the inventive matrix and the inventive TTS.

Abstract translation: 本发明涉及包含罗替戈汀的本发明的经皮治疗系统（TTS），包含苯乙烯丁二烯嵌段共聚物和结晶抑制剂的药学上可接受的粘合剂，本发明的具有适于透皮治疗系统的罗替戈汀释放的基质，本发明的生产方法 的相应基质或包含罗替戈汀的相应TTS，以及本发明的基质和本发明的TTS的用途。

公开(公告)号：WO2011000518A1

公开(公告)日：2011-01-06

申请号：PCT/EP2010/003857

申请日：2010-06-30

Applicant: ALFRED E. TIEFENBACHER (GMBH & CO. KG) ,  YOGANANDA, Chaitanya, Gujjar ,  BODDU, Srinath ,  RALLABANDI, BaIa, Ramesha, Chary ,  PASAHN, Manohar, LaI ,  FITZNER, Ansgar

Inventor： YOGANANDA, Chaitanya, Gujjar ,  BODDU, Srinath ,  RALLABANDI, BaIa, Ramesha, Chary ,  PASAHN, Manohar, LaI ,  FITZNER, Ansgar

IPC: A61K9/20 ,  A61K9/28

CPC classification number: A61K9/2018 ,  A61K9/2866 ,  A61K31/4545

Abstract: The present invention relates to a production process of a solid pharmaceutical composition in dosage form of a tablet comprising desloratadine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients and/or adjuvants including lactose, characterized in that a) desloratadine or the pharmaceutically acceptable salt thereof is present in a therapeutically effective amount and that b) the lactose is present as anhydrous lactose in an amount of 22 to 78 wt.-% based on the total weight of the solid pharmaceutical composition, the solid pharmaceutical composition in dosage form of a tablet obtainable by the inventive production process as well as uses thereof.

Abstract translation: 本发明涉及包含地氯雷他定或其药学上可接受的盐和一种或多种药学上可接受的赋形剂和/或佐剂（包括乳糖）的片剂剂型的固体药物组合物的制备方法，其特征在于a）地氯雷他定或药学上可接受的盐 其可接受的盐以治疗有效量存在，并且b）乳糖以固体药物组合物的总重量为基准，为22至78重量％的无水乳糖，固体药物组合物为剂型 的片剂，其可通过本发明的制备方法获得，以及其用途。

公开(公告)号：WO2023012376A2

公开(公告)日：2023-02-09

申请号：PCT/EP2022/077357

申请日：2022-09-30

Applicant: ALFRED E. TIEFENBACHER (GMBH & CO. KG)

Inventor： DÖBBER, Alexander ,  SAGILI, Manohar Reddy ,  GUJJAR, ChaitanyaYogananda ,  KALAMATA, Venkatasimhadri Naidu ,  FITZNER, Ansgar ,  MANKALA, Santhosh Kumar ,  RALLABANDI, Bala Ramesha Chary ,  MADALLAPALLI, Kiran Kumar

IPC: A61K31/55 ,  A61K9/2013 ,  A61K9/2095

Abstract: In the solid pharmaceutical compositions of the present invention, the formation of toxic N-nitroso-derivatives of the contained agents comprising a dialkylamino- or a trialkyl amino-group is prevented providing long-term storage stable formulations- of inherently problematic drugs, such as varenicline (e.g., in form of its tartrate or foe citrate). Means- for achieving the long-term storage stable formulations of the present invention are formulating the crucial active ingredients with antioxidants, using specific packaging materials for the pharmaceutical compositions- of the present invention, and/or employing specific manufacturing processes.

公开(公告)号：WO2014090386A1

公开(公告)日：2014-06-19

申请号：PCT/EP2013/003692

申请日：2013-12-06

Applicant: ALFRED E. TIEFENBACHER (GMBH & CO. KG)

Inventor： GUJJAR, Chaitanya Yogananda ,  RALLABANDI, Bala Ramesha Chary Rallabandi ,  PATWARI, Pradip Shivraj ,  FITZNER, Ansgar

IPC: A61K9/20 ,  A61K31/407

CPC classification number: A61K31/407 ,  A61K9/0053 ,  A61K9/0056 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2077 ,  A61K9/2095

Abstract: The present invention relates to an orally disintegrating tablet (ODT) containing asenapine maleate and to a process for preparing the ODT. In a first aspect, the present invention relates to an ODT containing asenapine maleate and low substituted hydroxypropylcellulose. In a second aspect, the present invention relates to an ODT containing crystalline asenapine maleate and the ODT is prepared using conventional tabletting techniques as direct compression and granulation. In a third aspect, the present invention relates to an ODT containing asenapine maleate and a carboxylic acid, and to the use of a carboxylic acid for enhancing storage stability of an asenapine maleate containing ODT.

Abstract translation: 本发明涉及含有马来酸二氮芥的口腔崩解片（ODT）及其制备方法。 在第一方面，本发明涉及含有马来酸asenapine和低取代羟丙基纤维素的ODT。 在第二方面，本发明涉及含有结晶阿拉芬那马来酸盐的ODT，并且使用常规压片技术制备ODT作为直接压制和造粒。 在第三方面，本发明涉及含有马来酸亚甲酯和羧酸的ODT，以及使用羧酸来提高含有ODT的马来酸阿萘那平的储存稳定性。

公开(公告)号：WO2022034232A1

公开(公告)日：2022-02-17

申请号：PCT/EP2021/072649

申请日：2021-08-13

Applicant: ALFRED E. TIEFENBACHER (GMBH & CO. KG)

Inventor： PRATHAP, Vamshi Ramana ,  KALAMATA, Venkatasimhadri Naidu ,  MUPKALKER, Ashwini Kumar ,  VELCHURI, Srikanth ,  RALLABANDI, Bala Ramesha Chary ,  MADALLAPALLI, Kiran Kumar ,  SCHLEHAHN, Hendrik ,  FITZNER, Ansgar

IPC: A61K9/14 ,  A61K9/20 ,  A61K31/496

Abstract: The present invention relates to a gastro-resistant high-strength unit dosage form comprising a solid solution prepared by hot-melt extrusion, whereby the solid solution contains 300 mg posaconazole and an enteric polymer in a specific weight ratio. The unit dosage form may be a capsule or optionally film-coated tablet.